felin
infecti
periton
signific
caus
mortal
domest
cat
worldwid
caus
virul
biotyp
felin
coronaviru
fcov
often
refer
felin
infecti
periton
viru
fipv
pedersen
member
famili
coronavirida
fcov
envelop
viru
nonseg
linear
singlestrand
positivesens
rna
genom
approxim
kb
fig
proxim
twothird
genom
contain
two
larg
open
read
frame
encod
nonstructur
replicas
protein
four
structur
protein
spike
envelop
e
membran
nucleocapsid
n
protein
sever
accessori
protein
unknown
function
encod
distal
one
third
genom
master
two
antigen
distinct
serotyp
fcov
type
type
ii
serotyp
differ
primarili
spike
protein
type
ii
virus
thought
arisen
recombin
event
canin
coronaviru
type
virus
consid
wholli
felin
herrewegh
et
al
type
fcov
commonli
isol
field
case
howev
vitro
studi
utilis
type
ii
strain
due
difficulti
propag
former
vitro
infect
fcov
extrem
common
domest
cat
demonstr
numer
seropreval
studi
addi
jarrett
bell
et
al
cave
et
al
holst
et
al
infect
asymptomat
unfortun
sequela
fcov
infect
subset
infect
cat
develop
fip
fip
occur
follow
exposur
virul
biotyp
fcov
either
de
novo
mutat
normal
avirul
fcov
within
individu
anim
call
intern
mutat
theori
chang
et
al
pedersen
et
al
poland
et
al
vennema
et
al
infect
virul
biotyp
felin
coronaviru
fcov
result
develop
felin
infecti
periton
fip
typic
fatal
immun
mediat
diseas
current
effect
antivir
treatment
studi
demonstr
abil
small
interf
rna
sirna
mediat
rna
interfer
rnai
inhibit
replic
virul
fcov
strain
fipv
wsu
immortalis
felin
cell
line
panel
eight
synthet
sirna
target
four
differ
region
fcov
genom
test
antivir
effect
efficaci
determin
qrtpcr
intracellular
viral
genom
messeng
rna
infect
assay
extracellular
viru
direct
ifa
viral
protein
express
sirna
demonstr
inhibitori
effect
viral
replic
vitro
two
effect
sirna
target
untransl
leader
sequenc
nucleocapsid
gene
result
reduct
extracellular
viral
titr
characteris
two
sirna
demonstr
efficaci
use
low
concentr
cell
challeng
high
viral
load
taken
togeth
find
provid
import
inform
potenti
therapeut
applic
rnai
treat
fip
elsevi
bv
right
reserv
recent
propos
exposur
circul
virul
strain
brown
et
al
regardless
origin
virul
fcov
biotyp
demonstr
enhanc
replic
cell
monocytemacrophag
lineag
thought
trigger
host
immun
dysregul
massiv
system
inflammatori
respons
seen
fip
pedersen
therapeut
option
cat
fip
extrem
limit
instanc
best
palli
review
hartmann
ritz
legendr
bartg
recent
report
use
novel
immunostimul
success
treatment
three
cat
noneffus
fip
agent
howev
effect
treat
common
effus
diseas
current
specif
antivir
chemotherapeut
agent
effect
treat
either
effus
noneffus
fip
although
number
drug
demonstr
vitro
efficaci
fcov
barlough
scott
barlough
shacklett
hsieh
et
al
keyaert
et
al
given
central
role
increas
fcov
replic
pathogenesi
fip
grootmijn
et
al
like
develop
effect
safe
antivir
agent
significantli
advanc
abil
treat
devast
condit
rna
interfer
rnai
highli
conserv
post
transcript
gene
silenc
mechan
found
eukaryot
recent
attract
signific
attent
due
potenti
therapeut
applic
rnai
induc
mammalian
cell
via
introduct
short
interf
rna
sirna
nucleotid
rna
duplex
introduc
sirna
incorpor
rna
induc
silenc
complex
risc
enabl
bind
target
complementari
sequenc
upon
bind
endonucleas
within
risc
cleav
target
mrna
result
sequenc
specif
gene
silenc
vitro
efficaci
rnai
antivir
therapeut
demonstr
rang
viral
pathogen
medic
veterinari
import
divers
viral
famili
includ
influenza
sar
coronaviru
foot
mouth
diseas
viru
ge
et
al
et
al
kahana
et
al
martinez
et
al
virus
find
extend
vivo
anim
model
induct
viru
specif
rnai
respons
result
reduct
viral
load
associ
patholog
li
et
al
tompkin
et
al
aim
studi
evalu
antivir
potenti
panel
eight
sirna
target
four
differ
region
fcov
genom
use
vitro
assay
effect
sirna
characteris
examin
effect
multipl
infect
sirna
concentr
inhibitori
effect
inform
gain
pilot
studi
essenti
first
step
develop
effect
rnai
base
treatment
fip
crandal
felin
kidney
crfk
cell
obtain
faculti
veterinari
scienc
univers
melbourn
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
foetal
bovin
serum
fb
sigmaaldrich
castl
hill
nsw
australia
cell
cultur
humidifi
incub
co
air
highli
virul
type
ii
fcov
strain
fipv
wsu
atcc
purchas
american
type
cultur
collect
atcc
manassa
va
usa
work
stock
viru
produc
crfk
cell
quantifi
plaqu
assay
plaqu
assay
perform
inocul
monolay
crfk
cell
plate
sarstedt
numbrecht
germani
ml
tenfold
viru
dilut
adsorpt
h
cell
overlaid
ml
mainten
media
contain
agaros
amresco
salon
oh
usa
h
incub
monolay
stain
ml
neutral
red
sigmaaldrich
h
plaqu
count
viru
stock
store
use
sirna
design
use
blockit
tm
rnai
design
invitrogen
mulgrav
vic
australia
use
consensu
sequenc
fipv
wsu
ascens
number
four
region
genom
target
membran
nucleocapsid
structur
gene
replicas
gene
common
leader
sequenc
gene
encod
spike
protein
main
structur
protein
target
studi
due
genet
divers
region
prospect
sirna
sequenc
align
report
fulland
partiallength
fcov
sequenc
avail
genbank
benson
et
al
use
geneiou
softwar
biomatt
ltd
auckland
nz
criteria
final
sirna
select
high
blockit
tm
rnai
design
rank
sequenc
homolog
report
fcov
strain
minimum
homolog
known
felin
sequenc
base
blast
search
use
select
criteria
two
highest
rank
sirna
target
four
region
select
tabl
fig
sirna
nscgfp
select
target
green
fluoresc
protein
mrna
act
nonsilenc
control
end
sens
strand
nscgfp
conjug
fluorescein
isothiocyan
fitc
enabl
transfect
efficaci
monitor
fluoresc
microscopi
lowpassag
subconflu
crfk
cell
use
experi
cell
dissoci
trypsin
edta
hbss
sigmaaldrich
cellswel
ad
tissu
cultur
plate
corn
inc
corn
ny
usa
h
prior
transfect
immunofluoresc
studi
monitor
transfect
efficaci
cell
plate
well
contain
steril
mm
glass
coverslip
proscitech
thuringowa
qld
australia
transfect
confluent
crfk
cell
perform
use
lipofectamin
invitrogen
per
manufactur
protocol
cell
monolay
wash
dmem
follow
h
transfect
period
efficaci
transfect
assess
time
use
epifluoresc
microscop
olympu
melvil
ny
usa
assess
percentag
cell
contain
intracytoplasm
fitc
cultur
infect
fipv
wsu
multipl
infect
moi
mock
infect
depend
experiment
requir
viru
allow
adsorb
min
follow
viral
inoculum
replac
fresh
mainten
media
sampl
harvest
variou
time
point
follow
infect
depend
experiment
requir
tissu
cultur
media
collect
store
prior
viru
titrat
assay
cellular
viral
rna
quantif
cell
monolay
lyse
rlt
buffer
qiagen
doncast
vic
australia
homogenis
lysat
store
prior
rna
extract
extracellular
viru
quantifi
use
tissu
cultur
infect
dose
assay
crfk
cell
harvest
tissu
cultur
media
clarifi
centrifug
g
min
supernat
serial
dilut
dmem
dilut
viru
suspens
ad
subconflu
monolay
crfk
cell
replic
well
well
plate
six
well
per
dilut
well
score
cytopath
effect
h
post
infect
use
olympu
invert
phasecontrast
microscop
olympu
endpoint
valu
calcul
accord
method
reed
muench
cell
grown
glass
coverslip
rins
pb
fix
methanolfre
formalin
polysci
warrington
pa
usa
pb
permeabilis
triton
sigmaaldrich
sampl
block
fb
pb
stain
fitc
conjug
antifelin
infecti
periton
viru
antiserum
vmrd
pullman
wa
usa
cell
counterstain
dapi
invitrogen
coverslip
mount
use
citifluor
antifad
citifluor
ltd
london
uk
imag
acquir
use
zeiss
lsm
meta
confoc
microscop
carl
zeiss
jena
germani
quantit
real
time
revers
transcriptas
pcr
qrtpcr
rna
extract
total
rna
extract
use
rneasi
mini
spin
column
qiagen
per
manufactur
protocol
includ
oncolumn
rnasefre
dnase
qiagen
treatment
rna
yield
puriti
determin
spectrophotometri
integr
rna
check
agaroseformaldehyd
denatur
gel
electrophoresi
purifi
rna
use
immedi
store
prior
cdna
synthesi
cdna
synthesi
cdna
gener
purifi
rna
use
superscript
iii
invitrogen
modifi
moloney
murin
leukaemia
viru
revers
transcriptas
final
reaction
volum
ml
reaction
consist
mg
purifi
rna
ng
random
primer
promega
alexandria
nsw
australia
mmol
dntp
promega
rnase
free
water
amresco
final
volum
ml
sampl
incub
min
denatur
rna
cool
ice
min
ad
mix
consist
ml
first
stand
buffer
invitrogen
unit
rnasin
plu
rnase
inhibitor
promega
unit
superscript
iii
tube
incub
min
follow
min
inactiv
revers
transcriptas
cdna
store
use
primer
design
use
softwar
rozen
skaletski
use
publish
sequenc
fipv
wsu
felin
gapdh
mrna
ascens
number
shown
tabl
posit
ident
forward
primer
n
gene
within
common
leader
sequenc
allow
differenti
subgenom
mrna
genom
rna
base
product
length
viru
specif
primer
design
target
conserv
region
fcov
genom
quantit
real
time
pcr
reaction
perform
use
rotorgen
cycler
corbett
life
scienc
mortlak
nsw
australia
target
amplifi
separ
ml
reaction
quadrupl
pcr
reaction
consist
ml
dilut
cdna
ml
gotaq
colorless
reaction
buffer
promega
pmol
forward
revers
primer
mmol
dntp
unit
gotaq
dna
polymeras
promega
ml
sybr
green
invitrogen
mmol
gapdh
fcov
genom
target
mmol
membran
nucleocapsid
mrna
target
mgcl
cycl
condit
gapdh
fcov
genom
nucleocapsid
mrna
follow
initi
denatur
dna
min
cycl
follow
final
extens
cycl
condit
amplifi
membran
mrna
ident
except
anneal
time
cycl
post
amplif
melt
curv
analysi
perform
per
degre
confirm
product
specif
reaction
serial
dilut
purifi
pcr
product
qiaquick
pcr
purif
kit
qiagen
amplifi
ident
condit
run
gener
standard
curv
copi
number
could
calcul
treatment
perform
triplic
result
express
geometr
mean
confid
interv
three
independ
experi
pcr
data
analysi
outlier
within
pcr
quadrupl
defin
valu
standard
deviat
mean
remain
replic
exclud
analysi
pcr
viral
genom
mrna
copi
number
normalis
housekeep
gene
gapdh
copi
number
rel
viral
copi
number
titr
calcul
divid
individu
treatment
tabl
primer
use
quantit
real
time
revers
transcriptas
pcr
primer
sequenc
product
size
valu
geometr
mean
untreat
sampl
statist
analysi
qrtpcr
viral
titr
data
log
transform
normalis
distribut
treatment
compar
oneway
anova
follow
dunnett
post
hoc
test
indic
graphpad
prism
window
graphpad
softwar
san
diego
ca
usa
pvalu
less
consid
signific
eight
sirna
design
studi
select
target
conserv
region
fcov
genom
visual
identifi
align
fulland
partiallength
fcov
sequenc
publish
genbank
use
method
abl
design
five
sirna
homolog
report
type
type
ii
strain
remain
sirna
show
complet
homolog
nucleotid
nucleotid
initi
screen
experi
conduct
eight
sirna
identifi
duplex
inhibitori
effect
fcov
replic
vitro
screen
experi
sirna
test
final
concentr
nm
efficaci
transfect
sirna
crfk
cell
greater
state
condit
associ
minim
toxic
data
shown
cell
infect
moi
untreat
cell
infect
mock
infect
cell
treat
transfect
reagent
without
sirna
cell
transfect
irrelev
nsc
sirna
includ
control
effect
sirna
viral
replic
determin
qrtpcr
intracellular
viru
detect
viral
genom
n
mrna
infect
assay
extracellular
viru
direct
ifa
stain
viral
antigen
conduct
hpi
addit
viru
induc
cpe
monitor
separ
well
hpi
sirna
test
result
statist
signific
inhibit
fcov
replic
measur
qrtpcr
infect
assay
howev
effect
sirna
target
treatment
lipofectamin
transfect
nsc
sirna
signific
effect
viral
replic
confirm
sequenc
specif
sirna
mediat
viral
inhibit
reduct
viral
genom
rna
fcov
specif
sirna
treat
cell
rang
fig
similar
result
seen
viral
mrna
mrna
knockdown
rang
fig
n
mrna
knockdown
rang
b
c
valu
express
geometr
mean
ae
confid
interv
three
independ
experi
asterick
indic
statist
signific
differ
treat
sampl
treatment
control
p
p
p
ns
signific
fig
reduct
extracellular
viru
titr
parallel
pcr
data
rang
confirm
viral
gene
knockdown
associ
signific
reduct
product
progeni
virion
fig
qualit
assess
viral
protein
express
use
direct
ifa
demonstr
treatment
fcov
specif
sirna
associ
reduct
number
cell
express
fcov
antigen
find
obviou
highli
effect
sirna
addit
phase
contrast
microscopi
show
viru
specif
sirna
provid
protect
viru
induc
cpe
case
h
post
infect
repres
micrograph
shown
fig
two
effect
sirna
target
use
examin
doserespons
relationship
respect
decreas
nm
concentr
fig
given
high
viral
load
demonstr
cat
fip
sought
determin
sirna
remain
effect
inhibit
fcov
replic
face
increas
viral
load
end
inhibitori
effect
sirna
fcov
replic
test
crfk
cell
use
transfect
infect
condit
ident
screen
experi
except
cell
infect
moi
sirna
efficaci
monitor
measur
extracellular
viru
titr
measur
intracellular
viral
genom
copi
infect
crfk
cell
fipv
wsu
high
multipl
infect
associ
signific
cytopath
effect
cell
loss
hpi
data
shown
allow
harvest
suffici
cell
determin
intracellular
viral
load
sampl
harvest
hpi
prior
develop
signific
cpe
although
extracellular
viru
test
hpi
demonstr
slight
increas
extracellular
fcov
titr
grown
crfk
cell
hpi
dewerchin
et
al
shown
fig
sirna
remain
effect
test
moi
inhibit
test
infect
condit
result
qrtpcr
viral
genom
show
less
pronounc
reduct
higher
moi
compar
viral
titr
result
differ
greatest
sirna
demonstr
reduct
viral
genom
copi
number
moi
rnai
demonstr
vitro
anim
model
potent
antivir
strategi
divers
rang
viral
pathogen
ge
et
al
et
al
kahana
et
al
martinez
et
al
current
studi
demonstr
effect
specif
sirna
mediat
rnai
substanti
inhibit
fcov
replic
vitro
without
cytopath
effect
felin
cell
line
provid
import
preliminari
data
potenti
effect
safeti
antivir
agent
lead
way
extens
vivo
anim
model
potenti
therapeut
agent
deadli
diseas
fip
current
effect
treatment
approach
may
also
potenti
applic
antivir
treatment
asymptomat
chronic
carrier
shedder
fcov
serv
continu
sourc
infect
cat
environ
although
like
high
cost
rnai
base
therapeut
may
preclud
widespread
applic
initi
screen
experi
conduct
identifi
sirna
could
effect
inhibit
fcov
replic
eight
sirna
test
target
differ
region
fcov
genom
includ
structur
gene
nonstructur
gene
untransl
region
select
appropri
sirna
target
critic
first
step
use
rnai
antivir
therapeut
baltimor
group
iv
viru
lifecycl
fcov
theoret
enabl
simultan
degrad
viral
genom
messeng
rna
via
rnai
addit
uniqu
discontinu
transcript
mechan
coronavirus
result
nest
set
subgenom
mrna
master
enabl
target
multipl
viral
mrna
viral
genom
rna
singl
sirna
common
leader
sequenc
play
critic
role
coronaviru
gene
express
present
end
viral
mrna
master
sirna
direct
untransl
leader
sequenc
target
viral
mrna
speci
report
effect
method
inhibit
coronaviru
replic
use
vitro
sarscov
model
li
et
al
similarli
number
paper
report
success
inhibit
replic
sarscov
target
region
encod
replicas
membran
nucleocapsid
protein
et
al
et
al
addit
complic
factor
design
sirna
use
fcov
genet
heterogen
inher
quasispeci
natur
rna
virus
ideal
antivir
sirna
therapeut
effect
field
isol
thu
conserv
region
viral
genom
target
strategi
may
also
help
limit
develop
escap
mutant
treatment
highli
conserv
region
like
structur
function
constrain
simpl
approach
sirna
design
abl
identifi
five
sirna
homolog
report
fcov
strain
advanc
approach
identifi
appropri
sirna
target
highli
diverg
virus
appli
naito
et
al
would
like
identifi
suitabl
conserv
target
effect
sirna
assess
genet
level
measur
viral
genom
messeng
rna
downstream
qualit
assess
viral
protein
synthesi
quantif
product
progeni
virion
sirna
test
demonstr
inhibitori
effect
fcov
replic
howev
magnitud
inhibit
vari
significantli
highli
effect
sirna
abl
reduc
extracellular
viru
titr
less
effect
sirna
result
reduct
approxim
variabl
potenc
differ
sirna
frequent
encount
rnai
studi
even
target
close
associ
region
demonstr
current
studi
sirna
result
greater
inhibit
extracellular
viral
titr
compar
sirna
despit
two
target
contigu
region
genom
treatment
magnitud
inhibit
determin
measur
viru
titr
greater
inhibit
seen
viral
genom
copi
number
although
two
assay
look
differ
endpoint
consist
discrep
may
part
explain
consid
qrtpcr
viral
genom
abl
detect
cleav
therefor
noninfecti
viral
genom
yet
degrad
thu
like
underestim
potenc
sirna
viral
mrna
also
assay
qrtpcr
sirna
target
structur
gene
knockdown
respect
mrna
greater
knockdown
viral
genom
find
may
due
viral
genom
least
partial
protect
effect
sirna
perhap
due
associ
viral
protein
critic
step
viru
assembl
genom
encapsid
n
protein
form
helic
nucleocapsid
master
tight
genomen
protein
interact
may
serv
partial
protect
progeni
genom
rnai
mediat
degrad
steric
hindranc
risc
access
target
site
suggest
virus
bitko
barik
hu
et
al
differ
rna
secondari
structur
smaller
viral
mrna
full
length
genom
copi
may
also
limit
target
site
access
shao
et
al
altern
differ
may
attribut
smaller
mrna
degrad
rapidli
follow
risc
mediat
cleavag
larger
full
length
genom
copi
studi
demonstr
two
effect
sirna
inhibit
fcov
replic
dose
depend
manner
importantli
highli
effect
sirna
still
abl
significantli
inhibit
fcov
replic
lowest
test
concentr
import
potenti
therapeut
point
view
offtarget
effect
associ
rnai
part
concentr
depend
behlk
thu
minimis
use
low
concentr
highli
potent
sirna
screen
titrat
experi
cell
infect
rel
low
moi
assess
use
sirna
therapeut
set
sirna
test
higher
moi
develop
fip
associ
high
viral
load
consid
higher
moi
would
accur
mimic
find
natur
infect
kipar
et
al
sirna
remain
effect
show
greater
inhibit
extracellular
viru
compar
control
sampl
even
challeng
increas
viru
earlier
experi
reduct
demonstr
viral
genom
copi
less
reduct
extracellular
viru
product
like
explan
qrtpcr
detect
noninfecti
cleav
genom
rna
prior
degrad
hypothesi
would
explain
significantli
increas
qrtpcr
result
compar
result
target
site
locat
pcr
primer
former
separ
kb
utilis
type
ii
fcov
fipv
wsu
studi
although
incid
type
ii
fcov
vari
worldwid
report
studi
infect
type
virus
common
type
ii
virus
pedersen
unlik
higher
preval
type
infect
would
invalid
therapeut
applic
sirna
test
studi
primari
differ
type
ii
fcov
spike
protein
region
target
test
sirna
addit
sirna
select
part
base
homolog
report
fcov
strain
includ
type
type
ii
fcov
therapeut
applic
rnai
technolog
face
number
import
challeng
translat
vitro
result
anim
model
requir
develop
appropri
deliveri
system
deliveri
option
rnai
includ
chemic
modif
sirna
duplex
lipidand
polymerbas
deliveri
system
akhtar
benter
direct
conjug
strategi
allow
target
deliveri
sirna
specif
tissu
cell
type
enhanc
activ
sirna
vivo
reduc
unwant
effect
akhtar
benter
addit
complic
associ
rnai
vivo
offtarget
effect
sirna
sequenc
use
studi
subject
blast
search
identifi
elimin
antifcov
sirna
signific
homolog
felin
gene
current
light
coverag
felin
genom
mean
homolog
felin
sequenc
may
miss
blast
search
result
unexpect
potenti
advers
offtarget
effect
depth
coverag
felin
genom
help
reduc
chanc
offtarget
effect
howev
mani
offtarget
effect
mediat
micro
rna
pathway
trigger
limit
sequenc
homolog
seed
region
sirna
jackson
linsley
appropri
talk
minimis
offtarget
effect
rather
avoid
behlk
taken
togeth
result
studi
suggest
rnai
may
use
therapeut
option
treatment
fip
howev
unlik
antivir
sirna
therapeut
antivir
therapeut
matter
effect
monotherapi
treat
fip
increas
viral
replic
trigger
perpetu
event
diseas
pathogenesi
characterist
patholog
lesion
widespread
seros
vascul
pyogranuloma
format
attend
clinic
sign
immunopatholog
natur
thu
effect
treatment
fip
like
requir
immunomodulatori
therapi
addit
antivir
therapi
result
current
studi
demonstr
sirna
mediat
rnai
may
appropri
choic
fulfil
latter
requir
